gt1a

UGT1A1-IN-1 (compound 2) acts as a non-competitive inhibitor of UGT1A1, effectively inhibiting the 1-O-glucuronidation process mediated by UGT1A1 with a Ki value of 5.02 μM. This compound binds to the same ligand-binding site on UGT1A1 as bilirubin and additionally functions as a 'turn-on' fluorescent probe substrate for UGT1A1 [1].

Ledipasvir D-tartrate with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon. is an inhibitor of the hepatitis C virus NS5A.

Grazoprevir is a drug approved for the treatment of hepatitis C. Grazoprevir is a second-generation hepatitis C virus protease inhibitor acting at the NS3 4a protease targets.

Grazoprevir, a second generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets, has good activity against a range of hepatitis C virus genotype variants, including some that are resistant to most currently used antiviral medic

ABT-072, also known as potassium trihydrate, is a highly effective non-nucleoside inhibitor of the HCV NS5B polymerase, administered orally. This compound exhibits potent activity against HCV GT1a (with an EC50 of 1 nM) and HCV GT1b (with an EC50 of 0.3 nM).

Ledipasvir (acetone) (GS-5885 acetone) is an HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

Grazoprevir (MK-5172) is a nitrogenous macrocyclic compound used as an inhibitor of the hepatitis C virus NS3 4A protease. Grazoprevir is commonly combined with elbasvir for treating chronic HCV genotype 1 or 4 infections in adults.

Ledipasvir (GS-5885) is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.

GSK5852 (GSK2485852) is an HCV NS5B RdRp polymerase inhibitor, inhibiting NS5B with an IC50 of 50 nM. It exhibits antiviral effects against the hepatitis C virus (HCV) with EC50 values of 3.0 nM for GT1a and 1.7 nM for GT1b.

HCV-IN-39 (Compound 18a) is a potent, orally active nucleoside inhibitor of hepatitis C virus (HCV), effective against the GT1a replicon (EC50: 0.259 μM), GT1b replicon (EC50: 0.434 μM), and GT1b CES1 replicon (EC50: 0.069 μM).

NS5A-IN-4 (Compound 1.12) is a pan-genotypic, orally active inhibitor of the hepatitis C virus (HCV) NS5A, with IC50 values of 1.2, 2296, 4.6, 362, 10.3, and 693 pM against genotypes gT1b, gT1a, gT2a, gT3a, gT4a, and gT5a, respectively [1].

Ledipasvir hydrochloride (GS-5885) is a hepatitis C virus NS5A inhibitor, demonstrating potent activity with EC50 values of 34 pM for genotype 1a replicon and 4 pM for genotype 1b replicon. It also functions as a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 µM [3].

HCV-IN-4, a potent and orally active inhibitor of HCV NS5A, demonstrates significant efficacy against genotypes GT1a, GT2b, GT3a, and the GT1a mutations Y93H and L31V. Its half-maximal effective concentrations (EC90s) are 3 pM, 0.3 nM, 0.01 nM, 0.5 nM, and 0.02 nM, respectively[1].